Why Pharma Data Scientists Spend 70% of Their Time on Data Engineering — And How Analysis-Ready RWD Changes That

The pharmaceutical industry has reached an inflection point. Real-world evidence isn’t a nice-to-have anymore—it’s the foundation for every major strategic decision, from market access negotiations to regulatory submissions to commercial forecasting. Yet here’s the uncomfortable truth most pharma executives won’t say out loud: your teams are drowning in data logistics instead of generating insights.

I’ve watched countless HEOR directors, market access leads, and data science teams spend 70-80% of their project timelines on what the New York Times famously called “janitor work”—sourcing, cleaning, linking, and harmonizing data from fragmented vendors. Meanwhile, payers are demanding robust value dossiers, regulators are expecting real-world evidence for label expansions, and competitors are moving faster because they’ve figured out how to skip the data engineering bottleneck.

The answer isn’t hiring more data engineers. And it isn’t spending months navigating a fragmented vendor landscape alone. It’s working with advisors who already know which data partnerships deliver for your specific use cases.

The DIY Data Engineering Quagmire: Why the Old Model Is Broken

Let me walk you through what most pharmaceutical companies experience when they need real-world data for a market access study or HEOR analysis.

First, you identify potential data sources. Claims data from one vendor. EHR data from another. Maybe specialty pharmacy data from a third. Each requires separate procurement cycles—legal reviews that stretch 3-6 months, contract negotiations with rigid multi-year commitments, and substantial upfront licensing fees before you’ve seen a single patient record.

Then comes the reality check. The data arrives in incompatible formats. One vendor uses ICD-10 codes, another uses a proprietary classification system. Date formats are inconsistent. Patient identifiers don’t match across sources, making longitudinal tracking nearly impossible without building complex probabilistic linkage algorithms.

Your expensive team of biostatisticians and data scientists—the people who should be building predictive models and generating insights—instead spend months writing ETL scripts, harmonizing code sets, validating data quality, and attempting to link records across disparate sources.

And here’s what keeps senior executives up at night: you’re navigating GDPR compliance alone, with every data handling decision carrying potential legal and reputational risk. One misstep in de-identification could result in regulatory penalties that dwarf your data licensing costs.

By the time you finally have an analysis-ready dataset, 6-12 months have elapsed. The market has evolved. Your competitor has already submitted their value dossier. That label expansion opportunity has cooled.

The cost isn’t just time—it’s the opportunity cost of elite scientific talent spending their days as data janitors instead of strategic advisors. The challenge many pharmaceutical companies face isn’t finding data providers—it’s determining which combination of capabilities genuinely aligns with their strategic priorities.

The Strategic Shift: Analysis-Ready Real-World Data

Now here’s what the most sophisticated pharmaceutical companies have figured out. They don’t build data infrastructure internally, and they don’t waste months evaluating dozens of vendors who all claim to offer the same thing. They work with advisors who understand both the pharmaceutical evidence landscape and the specific strengths of available data sources—and they get to first insight in weeks, not quarters.

Understanding Real-World Data (RWD) Sources

Real-world data encompasses the full spectrum of patient care outside controlled clinical trial environments. This includes insurance claims data (diagnoses, procedures, prescriptions), electronic health records (clinical notes, lab results, vital signs), patient registries, and pharmacy dispensing records.

What makes RWD valuable for pharmaceutical decision-making is its ability to answer questions clinical trials never asked. How does your drug perform in patients with multiple comorbidities? What’s the real-world treatment persistence at 12 months? How do healthcare costs change after patients switch from competitor therapies to yours?

Regulatory frameworks now explicitly recognize RWD’s role in supporting label expansions, post-market surveillance, and comparative effectiveness claims. The EMA and health technology assessment bodies across Continental Europe are accepting well-designed RWE studies for regulatory and reimbursement decisions.

But—and this is critical—the quality of your real-world evidence is directly constrained by the quality and readiness of your underlying data. Garbage in, garbage out isn’t just a data science cliché; it’s the reason payers reject value dossiers and regulators demand additional studies. Understanding which data sources match specific use cases requires deep market knowledge that most companies lack internally.

The Synthetic Data Revolution

Synthetic data represents one of the most significant innovations in healthcare analytics over the past decade. Think of it as privacy-preserving simulation—statistically representative patient records generated using advanced algorithms that preserve the patterns and relationships found in real data while containing zero actual patient information.

Why does this matter for pharmaceutical companies? Three reasons stand out.

First, it solves the access problem. For rare diseases or specific patient subpopulations where real-world data is scarce, synthetic data enables modeling and analysis that would otherwise be impossible. You can generate hypothetical cohorts matching precise inclusion criteria without waiting years to accrue sufficient real patient records.

Second, it dramatically accelerates AI and machine learning development. Training clinical algorithms requires massive datasets, but accessing enough real patient data for model development often triggers complex GDPR constraints. High-fidelity synthetic data provides a compliant alternative for initial model training, feature engineering, and algorithm validation before moving to real-world validation datasets.

Third, it enables scenario planning that’s impossible with historical data alone. What if disease prevalence increases by 15%? What if a new competitor enters with a novel mechanism of action? Synthetic data lets you model “what-if” scenarios without waiting for those scenarios to occur in your claims database.

The key scientific question is fidelity. Properly generated synthetic datasets preserve statistical properties—distributions, correlations, multivariate relationships—making them suitable for research, development, and exploratory analysis. They’re not appropriate for regulatory submissions requiring real patient outcomes, but they’re invaluable for de-risking projects, accelerating timelines, and testing hypotheses before committing to expensive real-world studies.

The Power of Combined & Linked Data

Here’s where most pharmaceutical analytics initiatives fail: they treat data sources as interchangeable commodities rather than recognizing that the highest value comes from strategic data integration.

Claims data alone tells you what procedures were billed and what prescriptions were filled. EHR data alone tells you clinical observations and lab results. But linking claims and EHR data at the patient level gives you a complete longitudinal view—from initial symptoms through diagnosis, treatment selection, outcomes, and long-term disease management.

This integration enables patient journey analytics that answer genuinely strategic questions. Where do patients typically receive their diagnosis? What diagnostic tests preceded treatment initiation? How long do patients persist on first-line therapy before switching? Which specialist referral patterns correlate with better outcomes?

Similarly, combining real-world data with synthetic data creates a powerful analytical framework. Use synthetic data for rapid hypothesis generation and algorithm development. Then validate findings using linked, multi-modal real-world datasets. This hybrid approach dramatically compresses timelines while maintaining scientific rigor for regulatory and payer audiences.

The gap between licensing claims data and extracting actionable intelligence is substantial—and this is precisely where expert guidance becomes critical. Building linked datasets internally requires sophisticated probabilistic matching algorithms, validation against known benchmarks, and continuous quality monitoring. The most efficient path is working with advisors who already understand which sources link well and for which therapeutic areas.

Navigating the Data Landscape: Key Considerations for Market Access Teams

When evaluating real-world data partnerships, you’re not just selecting a dataset—you’re making a strategic commitment that will either accelerate or constrain your evidence generation for years. The data landscape includes providers with meaningfully different strengths across several key dimensions, and navigating this landscape requires expertise in both pharmaceutical commercialization and the evolving real-world evidence ecosystem.

Compliance & Privacy: The Non-Negotiable Foundation

Any healthcare data source you consider must demonstrate rigorous GDPR compliance in actual data handling processes—not just marketing materials. For GDPR-governed datasets, this means documented de-identification methodology, evidence of appropriate technical and organizational measures, and clear data processing agreements.

International privacy frameworks like HIPAA establish complementary de-identification standards. Reputable data sources document which approach they apply and provide validation reports on request. For synthetic data specifically, methods like generative adversarial networks with differential privacy guarantees produce records that fall outside GDPR’s definition of personal data—but only when implemented correctly.

Most companies underestimate how complex this compliance evaluation is until they’re deep into procurement. Expert advisors who have already reviewed the compliance documentation of multiple providers can compress this assessment from months to days.

Analysis Readiness: The Dimension That Determines Your Timeline

Coverage breadth and geographic reach get most of the attention in vendor evaluations. Analysis readiness gets almost none—and it’s the factor that most directly determines whether your project delivers in weeks or gets stuck in a data engineering quagmire for months.

Genuinely analysis-ready data includes standardized, validated coding systems (ICD-10 diagnoses, procedure codes, prescription classifications), pre-built data models for common pharmaceutical use cases, and quality-validated longitudinal records with enrollment periods and lookback windows already applied. It comes with clear data dictionaries you can actually use on day one.

The distinction between “raw data” and “analysis-ready data” sounds technical, but its business impact is enormous. One approach has your scientists generating insights within days. The other has them writing ETL scripts for the next quarter. Most providers don’t volunteer which category they fall into.

Coverage, Scope & Geographic Granularity

Coverage breadth varies dramatically across providers. Some maintain comprehensive longitudinal records covering hundreds of millions of patient lives across multiple regions and payer types. Others focus on specific geographies or populations with greater clinical depth. Neither is universally superior—the right choice depends entirely on your use case.

For pan-European market access strategies, understanding regional variation across Continental Europe is particularly important. Healthcare system structures differ substantially—from Nordic universal models to Swiss mandatory insurance frameworks to mixed public-private systems in Eastern and Southern Europe. Datasets with appropriate regional granularity enable insights that national averages obscure.

Linkage depth is equally critical. Ask specifically: What percentage of patients can be tracked longitudinally for 1 year? For 3 years? Databases that can’t link patients across payers or over time create systematic blind spots in treatment persistence analyses. Patient journey and trajectory mapping are impossible without robust longitudinal linkage.

Analytical Sophistication & Use Case Fit

Analytical capabilities range from traditional query-based systems to AI-powered platforms offering real-time pattern recognition and predictive analytics. Neither is inherently better—the choice depends on whether you need descriptive intelligence or forward-looking insights, and whether your team prefers self-service tools or full-service analytical support.

For market access and HEOR teams, you need data that supports health economics and outcomes research with sufficient clinical detail for comparative effectiveness studies and cost-effectiveness modeling. For commercial analytics teams, you need market intelligence with competitor visibility and prescriber granularity. For R&D teams, you need data supporting trial feasibility and phenotype validation for cohort identification.

Understanding which combination of capabilities aligns with your specific strategic priorities requires careful evaluation of both your use cases and the provider landscape. Most companies discover—often expensively—that the dataset they licensed for one use case is poorly suited for the next project.

Synthetic Data Fidelity & Validation

If synthetic data is part of your evaluation, validation methodology is paramount. Reputable sources conduct multi-dimensional validation: univariate (do individual variable distributions match the source data?), bivariate (are comorbidity correlations preserved?), and multivariate (do complex treatment sequence patterns hold when models are trained on synthetic versus real data?).

Published validation frameworks provide the scientific basis for this assessment. Any provider claiming their synthetic data is “indistinguishable from real data” should produce multi-dimensional validation reports on request. And critically: synthetic data is excellent for hypothesis generation, scenario modeling, and machine learning development—it is not appropriate for regulatory submissions or primary payer evidence. Advisors who understand both the science and the regulatory context can help you deploy synthetic data where it creates genuine value without overreaching its legitimate applications.

Getting Started: From Requirements to the Right Data Partnership

The path from recognizing a data need to generating actionable insights has several distinct stages—and where most companies lose time is not in the analysis itself, but in the poorly structured decisions that precede it.

Define requirements before evaluating options. Document your coverage needs (geographies, therapeutic areas, patient populations), analytical capabilities (self-service vs. full-service), integration requirements, GDPR compliance constraints, and budget parameters. This clarity prevents costly mismatches. Expert consultants can help structure this requirements definition process to ensure you’re comparing options on the dimensions that actually matter for your specific use cases.

Understand the landscape dimensions before talking to vendors. The healthcare data market includes dozens of providers with overlapping but distinct capabilities. Key dimensions include data recency (real-time vs. adjudicated), geographic coverage and regional granularity, therapeutic depth, analytical tooling, GDPR compliance documentation, and cost models. Walking into vendor conversations without a clear evaluation framework means your procurement process will be driven by whoever has the best sales team, not the best data fit.

Leverage expert guidance for vendor selection. The gap between understanding what real-world data can do and identifying which specific provider matches your needs is substantial. Predictive modeling, patient trajectory analysis, and robust HEOR studies each place different demands on data architecture. Advisors who understand both pharmaceutical decision-making and the vendor landscape can accelerate your path to value while steering you away from the common pitfall of licensing data that looks comprehensive on paper but can’t answer your actual questions.

Pilot before scaling. Start with a focused project to validate that your chosen approach answers your questions before committing to large-scale, multi-year licensing agreements. Expert advisors can help structure pilots that generate genuine signal about data fit, not just vendor-led demonstrations designed to highlight strengths.

The Real Strategic Advantage: Speed and Certainty

The pharmaceutical industry is evolving toward a model where data is strategic utility—reliably available, consistently high-quality, immediately usable—rather than an internal engineering project. This shift enables pharmaceutical companies to focus elite scientific talent on the work that actually matters: generating evidence that drives drug approval, secures favorable reimbursement, and builds commercial success.

Pharmaceutical companies that navigate this landscape strategically—with clear requirements, the right data partnerships, and expert guidance through vendor selection—consistently demonstrate 3-6 month advantages in time-to-insight across market access, forecasting, and commercial analytics projects. That time advantage compounds. Faster market access evidence generation accelerates reimbursement negotiations. Earlier competitive intelligence improves launch planning. Quicker patient journey analysis informs more effective commercial strategies.

The goal isn’t to “buy data.” The goal is to purchase speed, certainty, and strategic flexibility—enabling your teams to focus on generating the insights and evidence that differentiate your company in competitive markets. Getting there efficiently requires knowing not just what data exists, but which combination of sources, capabilities, and partnerships fits your specific situation.

Sources & References

1. U.S. Food and Drug Administration (FDA). (2023). Real-World Evidence. https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence
2. Berger, M. L., et al. (2017). A Framework for Regulatory Use of Real-World Evidence. Journal of Comparative Effectiveness Research, 6(1), 5-8. https://www.tandfonline.com/doi/full/10.2217/cer-2016-0047
3. Lohr, S. (2014). For Big-Data Scientists, ‘Janitor Work’ Is Key Hurdle to Insights. The New York Times. https://www.nytimes.com/2014/08/18/technology/for-big-data-scientists-hurdle-to-insights-is-janitor-work.html
4. Yale University & Mayo Clinic. (2021). Synthetic Data in Health Care: A Narrative Review. NEJM Catalyst. https://catalyst.nejm.org/doi/full/10.1056/CAT.20.0522
5. Goncalves, A., et al. (2020). Generation and Evaluation of Synthetic Patient Data. BMC Medical Research Methodology, 20, 108. https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/s12874-020-00977-1
6. Chen, R. J., et al. (2021). Synthetic data in machine learning for medicine and healthcare. Nature Biomedical Engineering, 5, 493–497. https://www.nature.com/articles/s41551-021-00751-8
7. Richesson, R. L., & Hammond, W. E. (2020). Electronic Health Record Data for Clinical Research: A Data Quality Perspective. In R. L. Richesson & J. E. Andrews (Eds.), Clinical Research Informatics. Springer. https://link.springer.com/chapter/10.1007/978-3-030-29382-0_10
8. ISPOR (The Professional Society for Health Economics and Outcomes Research). (2022). What is HEOR? https://www.ispor.org/heor-resources/about-heor
9. Jensen, P. B., Jensen, L. J., & Brunak, S. (2012). Mining electronic health records: towards better research applications and clinical care. Nature Reviews Genetics, 13, 395–405. https://www.nature.com/articles/nrg3208
10. Wessler, B. S., et al. (2015). External Validations of Cardiovascular Clinical Prediction Models: A Large-Scale Review of the Literature. Circulation: Cardiovascular Quality and Outcomes, 8(1), 104-112. https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.114.001324
11. Hripcsak, G., & Albers, D. J. (2013). Next-generation phenotyping of electronic health records. Journal of the American Medical Informatics Association, 20(1), 117–121. https://academic.oup.com/jamia/article/20/1/117/2903051
12. U.S. Department of Health & Human Services. (2024). Health Information Privacy (HIPAA). https://www.hhs.gov/hipaa/index.html

---

previous post: https://medddical.com/data-enrichment-for-pharma/aggregated-and-synthetic-insurance-data-what-it-is-why-it-matters-and-where-it-is-used/

next post: https://medddical.com/real-world-evidence-strategy-and-analytics/analysis-ready-real-world-evidence-and-healthcare-data-for-pharma/